Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic BMT for High Risk Hemoglobinopathies
NCT00040469Phase 2Terminated
- Sponsor
- Baylor College of Medicine
- Start
- Aug 2000
- Primary completion
- Nov 2003
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in sickle cell anemia (SCA), thalassemia, sponsored by Baylor College of Medicine. Started Aug 2000; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
sickle cell anemia (SCA)thalassemia
Beyond the preview
Go deeper on NCT00040469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00040469.